Category Archives: Biotechnology

Intellia Therapeutics Inc (NTLA) is around the top of the Biotechnology industry according to InvestorsObserver. NTLA received an overall rating of 63, which means that it scores higher than 63 percent of all stocks. Intellia Therapeutics Inc also achieved a score of 94 in the Biotechnology industry, putting it above 94 percent of Biotechnology stocks. Biotechnology is ranked 103 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 63 would rank higher than 63 percent of all stocks.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Intellia Therapeutics Inc (NTLA) stock has fallen -3.98% while the S&P 500 has risen 0.68% as of 2:37 PM on Friday, Jul 2. NTLA has fallen -$6.83 from the previous closing price of $171.65 on volume of 2,294,617 shares. Over the past year the S&P 500 is up 38.95% while NTLA has risen 639.10%. NTLA lost -$2.46 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Intellia Therapeutics Inc (NTLA) Stock.

Read the original post:
Where Does Intellia Therapeutics Inc (NTLA) Stock Fall in the Biotechnology Field After It Is Up 85.55% This Week? - InvestorsObserver

Vir Biotechnology Inc (VIR) is around the top of the Biotechnology industry according to InvestorsObserver. VIR received an overall rating of 44, which means that it scores higher than 44 percent of all stocks. Vir Biotechnology Inc also achieved a score of 70 in the Biotechnology industry, putting it above 70 percent of Biotechnology stocks. Biotechnology is ranked 103 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Vir Biotechnology Inc (VIR) stock has fallen -4.14% while the S&P 500 is higher by 0.68% as of 2:38 PM on Friday, Jul 2. VIR is lower by -$1.80 from the previous closing price of $43.53 on volume of 529,054 shares. Over the past year the S&P 500 has risen 38.95% while VIR is higher by 3.50%. VIR lost -$3.10 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Vir Biotechnology Inc (VIR) Stock.

Read the original:
Vir Biotechnology Inc (VIR) is lower by -8.31% in a Week, Should You Buy? - InvestorsObserver

The 53 rating InvestorsObserver gives to Aldeyra Therapeutics Inc (ALDX) stock puts it near the top of the Biotechnology industry. In addition to scoring higher than 86 percent of stocks in the Biotechnology industry, ALDXs 53 overall rating means the stock scores better than 53 percent of all stocks.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

This ranking system incorporates numerous factors used by analysts to compare stocks in greater detail. This allows you to find the best stocks available in any industry with relative ease. These percentile-ranked scores using both fundamental and technical analysis give investors an easy way to view the attractiveness of specific stocks. Stocks with the highest scores have the best evaluations by analysts working on Wall Street.

Aldeyra Therapeutics Inc (ALDX) stock has fallen -2.92% while the S&P 500 has risen 0.68% as of 2:50 PM on Friday, Jul 2. ALDX has fallen -$0.33 from the previous closing price of $11.31 on volume of 434,186 shares. Over the past year the S&P 500 is higher by 38.95% while ALDX has risen 163.31%. ALDX lost -$1.02 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Aldeyra Therapeutics Inc (ALDX) Stock.

See the rest here:
Is Aldeyra Therapeutics Inc (ALDX) a Winner in the Biotechnology Industry? - InvestorsObserver

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) approved a labeling supplement to the U.S. Prescribing Information for NERLYNX that incorporates the use of NERLYNX dose escalation as evaluated in the Phase II CONTROL Trial and the new 133 count commercial NERLYNX SKU. The new 133 count SKU, i.e., a bottle containing a four-week supply of 133 tablets, is aligned with the use of NERLYNX dose escalation and designed to better support patient needs.

The CONTROL study was a multicenter, open-label, multi-cohort trial evaluating patients with early stage HER2-positive breast cancer treated with NERLYNX 240 mg daily for up to one year who received loperamide prophylaxis with additional anti-diarrheal treatment as needed (PRN) or NERLYNX dose escalation with loperamide as needed. Patients in the dose escalation cohort received NERLYNX 120 mg daily for Week 1, followed by NERLYNX 160 mg daily for Week 2, followed by NERLYNX 240 mg daily for Week 3 and thereafter for the duration of treatment.

Data from this study showed that dose escalation in the extended adjuvant setting, coupled with PRN Loperamide, led to a greater than 60% reduction in the percentage of patients who experienced Grade 3 diarrhea (40% vs. 13%), a 50% reduction in median cumulative days of Grade 3 diarrhea (5 days vs. 2.5 days) and an approximate 80% reduction in discontinuation rates (17% vs. 3%) when compared to ExteNET, where no dose escalation or antidiarrheal prophylaxis was mandated.

Hope S. Rugo, MD, Professor of Medicine at the University of California San Francisco Comprehensive Cancer Center, said, The inclusion of dose escalation in the prescribing information is a critical road-map for health care providers and patients as they seek to optimize treatment and reduce therapy-related toxicity in the early breast cancer and metastatic settings.

Alan H. Auerbach, Chief Executive Officer and President of Puma, said, We believe that utilizing dose escalation has the potential to improve the overall tolerability of NERLYNX and increase the average length of therapy, with the end result benefiting more patients battling breast cancer.

About HER2-Positive Breast Cancer

Up to 20% of patients with breast cancer tumors over-express the HER2 protein (HER2-positive disease) and in the ExteNET study, 57% of patients were found to have tumors that were hormone-receptor positive. HER2-positive breast cancer is often more aggressive than other types of breast cancer, increasing the risk of disease progression and death. Although research has shown that trastuzumab can reduce the risk of early stage HER2-positive breast cancer recurring, up to 25% of patients treated with trastuzumab experience recurrence within 10 years, the majority of which are metastatic recurrences.

About Puma Biotechnology

Puma Biotechnology, Inc. is a biopharmaceutical company with a focus on the development and commercialization of innovative products to enhance cancer care. Puma in-licenses the global development and commercialization rights to PB272 (neratinib, oral), PB272 (neratinib, intravenous) and PB357. Neratinib, oral was approved by the U.S. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNX (neratinib) tablets. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. NERLYNX is a registered trademark of Puma Biotechnology, Inc.

Further information about Puma Biotechnology may be found at http://www.pumabiotechnology.com.

IMPORTANT SAFETY INFORMATION

NERLYNX (neratinib) tablets, for oral use

INDICATIONS AND USAGE: NERLYNX is a kinase inhibitor indicated:

CONTRAINDICATIONS: None

WARNINGS AND PRECAUTIONS:

ADVERSE REACTIONS:

The most common adverse reactions (reported in 5% of patients) were as follows:

To report SUSPECTED ADVERSE REACTIONS, contact Puma Biotechnology, Inc. at 1-844-NERLYNX (1-844-637-5969) or FDA at 1-800-FDA-1088 or http://www.fda.gov/medwatch.

DRUG INTERACTIONS:

USE IN SPECIFIC POPULATIONS:

Please see Full Prescribing Information for additional safety information.

To help ensure patients have access to NERLYNX, Puma has implemented the Puma Patient Lynx support program to assist patients and healthcare providers with reimbursement support and referrals to resources that can help with financial assistance. More information on the Puma Patient Lynx program can be found at http://www.NERLYNX.com or 1-855-816-5421.

Forward-Looking Statement

This press release contains forward-looking statements, that involve risks and uncertainties that could cause Pumas actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors, which include, but are not limited to, any adverse impact on Pumas business or the global economy and financial markets, generally, from the global COVID-19 pandemic, and the risk factors disclosed in the periodic and current reports filed by Puma with the Securities and Exchange Commission from time to time, including Pumas Annual Report on Form 10-K for the year ended December 31, 2020. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. Puma assumes no obligation to update these forward-looking statements, except as required by law.

See the rest here:
FDA Approves Dose Escalation Label Update for Puma Biotechnology's NERLYNX (neratinib) in HER2-Positive Early Stage and Metastatic Breast Cancer -...

A rating of 83 puts Infinity Pharmaceuticals Inc. (INFI) near the top of the Biotechnology industry according to InvestorsObserver. Infinity Pharmaceuticals Inc.'s score of 83 means it scores higher than 83% of stocks in the industry. Infinity Pharmaceuticals Inc. also received an overall rating of 51, putting it above 51% of all stocks. Biotechnology is ranked 103 out of the 148 industries.

Trying to find the best stocks can be a daunting task. There are a wide variety of ways to analyze stocks in order to determine which ones are performing the strongest. Investors Observer makes the entire process easier by using percentile rankings that allows you to easily find the stocks who have the strongest evaluations by analysts.

These scores are not only easy to understand, but it is easy to compare stocks to each other. You can find the best stock in an industry, or look for the sector that has the highest average score. The overall score is a combination of technical and fundamental factors that serves as a good starting point when analyzing a stock. Traders and investors with different goals may have different goals and will want to consider other factors than just the headline number before making any investment decisions.

Infinity Pharmaceuticals Inc. (INFI) stock is down -5.09% while the S&P 500 has gained 0.68% as of 2:37 PM on Friday, Jul 2. INFI is down -$0.15 from the previous closing price of $3.00 on volume of 1,497,109 shares. Over the past year the S&P 500 has risen 38.95% while INFI has gained 220.22%. INFI lost -$0.64 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Infinity Pharmaceuticals Inc. (INFI) Stock.

Read more:
Where Does Infinity Pharmaceuticals Inc. (INFI) Stock Fall in the Biotechnology Field After It Is Down -5.32% This Week? - InvestorsObserver

A rating of 20 puts Puma Biotechnology Inc (PBYI) near the bottom of the Biotechnology industry according to InvestorsObserver. Puma Biotechnology Inc's score of 20 means it scores higher than 20% of stocks in the industry. Puma Biotechnology Inc also received an overall rating of 26, putting it above 26% of all stocks. Biotechnology is ranked 103 out of the 148 industries.

Searching for the best stocks to invest in can be difficult. There are thousands of options and it can be confusing on what actually constitutes a great value. Investors Observer allows you to choose from eight unique metrics to view the top industries and the best performing stocks in that industry. A score of 26 would rank higher than 26 percent of all stocks.

These rankings allows you to easily compare stocks and view what the strengths and weaknesses are of a given company. This lets you find the stocks with the best short and long term growth prospects in a matter of seconds. The combined score incorporates technical and fundamental analysis in order to give a comprehensive overview of a stocks performance. Investors who then want to focus on analysts rankings or valuations are able to see the separate scores for each section.

Puma Biotechnology Inc (PBYI) stock is lower by -6.07% while the S&P 500 has risen 0.68% as of 2:51 PM on Friday, Jul 2. PBYI is down -$0.57 from the previous closing price of $9.39 on volume of 324,503 shares. Over the past year the S&P 500 has gained 38.95% while PBYI is down -16.24%. PBYI lost -$0.68 per share the over the last 12 months.

Click Here to get the full Stock Score Report on Puma Biotechnology Inc (PBYI) Stock.

Original post:
Does Puma Biotechnology Inc (PBYI) Have What it Takes to be in Your Portfolio Friday? - InvestorsObserver